Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin

A Kolstad; A. Laurell; M. Jerkeman; K. Grønbæk; E. Elonen; R. Räty; LB Pedersen; A. Loft; TV. Bogsrud; M. Nordstrøm; PB. Hansen; U. Fagerli; H. Nilsson-Ehle; GF. Lauritzsen; AK. Lehmann; C. Sundstrom; M. Karjalainen-Lindsberg; E.  Ralfkiaer; M. Ehinger; J. Delabie; H. Bentzen; J. Schildt; K. Kostova-Aherdan; Henrik Frederiksen; Peter De Nully Brown; CH. Geisler

Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin

A Kolstad, A. Laurell, M. Jerkeman, K. Grønbæk, E. Elonen, R. Räty, LB Pedersen, A. Loft, TV. Bogsrud, M. Nordstrøm, PB. Hansen, U. Fagerli, H. Nilsson-Ehle, GF. Lauritzsen, AK. Lehmann, C. Sundstrom, M. Karjalainen-Lindsberg, E. Ralfkiaer, M. Ehinger, J. DelabieH. Bentzen, J. Schildt, K. Kostova-Aherdan, Henrik Frederiksen, Peter De Nully Brown, CH. Geisler

KI, OUH, Research unit of Haematology (Odense)

Research output: Contribution to conference without publisher/journal › Conference abstract for conference › Research

Original language	English
Publication date	Dec 2012
Publication status	Published - Dec 2012
Event	American Society of Hematology Annual Meeting 2012, Atlanta - Atlanta, Georgia., Atlanta, GA., United States Duration: 8. Dec 2012 → 11. Dec 2012

Conference

Conference	American Society of Hematology Annual Meeting 2012, Atlanta
Location	Atlanta, Georgia.
Country/Territory	United States
City	Atlanta, GA.
Period	08/12/2012 → 11/12/2012

Cite this

Kolstad, A., Laurell, A., Jerkeman, M., Grønbæk, K., Elonen, E., Räty, R., Pedersen, LB., Loft, A., Bogsrud, TV., Nordstrøm, M., Hansen, PB., Fagerli, U., Nilsson-Ehle, H., Lauritzsen, GF., Lehmann, AK., Sundstrom, C., Karjalainen-Lindsberg, M., Ralfkiaer, E., Ehinger, M., ... Geisler, CH. (2012). Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin. Abstract from American Society of Hematology Annual Meeting 2012, Atlanta, Atlanta, GA., United States.

Kolstad, A ; Laurell, A. ; Jerkeman, M. et al. / Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin. Abstract from American Society of Hematology Annual Meeting 2012, Atlanta, Atlanta, GA., United States.

@conference{6e746317e37b4992a4bb129b490b871c,

title = "Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin",

author = "A Kolstad and A. Laurell and M. Jerkeman and K. Gr{\o}nb{\ae}k and E. Elonen and R. R{\"a}ty and LB Pedersen and A. Loft and TV. Bogsrud and M. Nordstr{\o}m and PB. Hansen and U. Fagerli and H. Nilsson-Ehle and GF. Lauritzsen and AK. Lehmann and C. Sundstrom and M. Karjalainen-Lindsberg and E. Ralfkiaer and M. Ehinger and J. Delabie and H. Bentzen and J. Schildt and K. Kostova-Aherdan and Henrik Frederiksen and Brown, {Peter De Nully} and CH. Geisler",

year = "2012",

month = dec,

language = "English",

note = "American Society of Hematology Annual Meeting 2012, Atlanta ; Conference date: 08-12-2012 Through 11-12-2012",

}

Kolstad, A, Laurell, A, Jerkeman, M, Grønbæk, K, Elonen, E, Räty, R, Pedersen, LB, Loft, A, Bogsrud, TV, Nordstrøm, M, Hansen, PB, Fagerli, U, Nilsson-Ehle, H, Lauritzsen, GF, Lehmann, AK, Sundstrom, C, Karjalainen-Lindsberg, M, Ralfkiaer, E, Ehinger, M, Delabie, J, Bentzen, H, Schildt, J, Kostova-Aherdan, K, Frederiksen, H, Brown, PDN & Geisler, CH 2012, 'Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin', American Society of Hematology Annual Meeting 2012, Atlanta, Atlanta, GA., United States, 08/12/2012 - 11/12/2012.

Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin. / Kolstad, A; Laurell, A.; Jerkeman, M. et al.

2012. Abstract from American Society of Hematology Annual Meeting 2012, Atlanta, Atlanta, GA., United States.

Research output: Contribution to conference without publisher/journal › Conference abstract for conference › Research

TY - ABST

T1 - Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin

AU - Kolstad, A

AU - Laurell, A.

AU - Jerkeman, M.

AU - Grønbæk, K.

AU - Elonen, E.

AU - Räty, R.

AU - Pedersen, LB

AU - Loft, A.

AU - Bogsrud, TV.

AU - Nordstrøm, M.

AU - Hansen, PB.

AU - Fagerli, U.

AU - Nilsson-Ehle, H.

AU - Lauritzsen, GF.

AU - Lehmann, AK.

AU - Sundstrom, C.

AU - Karjalainen-Lindsberg, M.

AU - Ralfkiaer, E.

AU - Ehinger, M.

AU - Delabie, J.

AU - Bentzen, H.

AU - Schildt, J.

AU - Kostova-Aherdan, K.

AU - Frederiksen, Henrik

AU - Brown, Peter De Nully

AU - Geisler, CH.

PY - 2012/12

Y1 - 2012/12

M3 - Conference abstract for conference

T2 - American Society of Hematology Annual Meeting 2012, Atlanta

Y2 - 8 December 2012 through 11 December 2012

ER -

Kolstad A, Laurell A, Jerkeman M, Grønbæk K, Elonen E, Räty R et al.. Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin. 2012. Abstract from American Society of Hematology Annual Meeting 2012, Atlanta, Atlanta, GA., United States.